CVR 39720213Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)GlostrupFounded 9 Jul 2018
Gross profit
10.3M
DKK, annual report 2025
+50.2% on 2024
Result
+8.1M
DKK, annual report 2025
Equity
20.3M
DKK, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about hameln pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up Dandexhameln pharma gmbh100% of capital and votes, since 9 Jul 2018
Stephen Allen Watkinsince 9 Jul 2018
Frank Jahrandsince 5 Jul 2021
100% of capital and votessince 9 Jul 2018
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
9 Jul 2018 to 22 Oct 2026.
9 Jul 2018 to 22 Oct 2026.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 1,874 | 2,613 | 3,130 | 6,857 | 10,300 |
| Operating profit | +1,874 | Not reported | Not reported | Not reported | Not reported |
| Result for the year | +1,417 | +1,910 | +2,325 | +5,289 | +8,051 |
| Equity | 3,248 | 5,044 | 7,377 | 12,297 | 20,335 |
| Total assets | 5,207 | 9,435 | 15,534 | 18,628 | 24,369 |
| Employees (average) | 0 | 0 | 0 | 0 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | -22% | 39.4% | 19.8% | 119% | 50.2% |
| EBITDA | 1,874 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) | 100% | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -667note 2 | -2,719note 2 | -1,913note 2 | -6,947note 2 | -8,661note 2 |
| Gearing, NIBD / EBITDA | Net cashnote 2 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 |
| ROIC (afkast af investeret kapital) | 265.8%note 2 | 82.9%note 3 | 62.6%note 3 | 97.8%note 3 | 94.2%note 3 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 767note 2 | -302note 2 | 1,212note 2 | -3,858note 2 | -6,963note 2 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement filed (class A and B are exempt).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 4 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 10 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 14 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 3 Jul 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 6 Apr 2022
hameln pharma ApS has moved to a new address, with a potential need for new suppliers.
Signal, a Dandex estimate. Lapses 7 Jan 2027.
1 registered in CVR.
P-number 1023790293Naverland 22, 2600 Glostrup
No other current company drawn.
No other current company drawn.
